[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Views 3,313
Citations 0
Clinical Trials Update
June 23/30, 2020

Prostate Cancer Drug Degarelix Rapidly Treats Pedophilic Disorder

JAMA. 2020;323(24):2453. doi:10.1001/jama.2020.10336

Degarelix, an advanced prostate cancer drug, rapidly reduced the risk of committing child sexual abuse among men with pedophilic disorder, a phase 2 trial in JAMA Psychiatry found.

The study involved 52 men in Sweden who were diagnosed with and seeking treatment for pedophilic disorder. They were randomly assigned to receive either 2 subcutaneous injections of degarelix acetate or a placebo.

At 2 weeks, the composite risk score of 5 domains of child sexual abuse (range, 0-15 points) decreased from 7.4 to 4.4 among participants in the degarelix group and from 7.8 to 6.6 in the placebo group. A decrease in risk score was also seen at 10 weeks in the treatment group.

Degarelix is a gonadotropin-releasing hormone antagonist that decreases testosterone to castration levels within 3 days without initial testosterone flare-ups seen with similar drugs. With further study, the fast-acting drug plus psychosocial support may be suitable for long-term treatment, the authors noted.